Thursday, January 16, 2014

Iguratimod at the ACR 2013 Meeting in San Diego

Iguratimod (T-614) is a novel disease modifying anti-rheumatic drug (DMARD). Iguratimod is characterized by inhibitory effects on immunoglobulin production in B cells as well as inhibiting cytokine production. Its' mode of action comes by suppression of nuclear factor kappa B (NF-kB) activation. As I have already written this before, please look for the links below. 2012 there had been three studies, 2013 one study at the EULAR Meeting in Madrid (a study by a Chinese group).

There has only been on study at the ACR 2013 Meeting. Daisuke Kobayashi and colleagues published the following study [#1422]: “Efficacy and Safety Of a Novel Disease-Modifying Antirheumatic Drug, Iguratimod, As Add-On Therapy For Patients With Rheumatoid Arthritis.” The study has been small (N=26). Conclusion: “Iguratimod is effective as add-on therapy in RA patients who have shown inadequate responses to previous therapy, although caution is necessary regarding hemorrhagic tendency in patients receiving warfarin, which was cautioned by Ministry of Health, Labour and Welfare of Japan.”

I think iguratimod is indeed a promising candidate for treatment of active rheumatoid arthritis and might become a needed alternative in the conventional (traditional) DMARD class. I wished the sponsor would press more for results, also for studies, which would result in an appearance on the world market.


No comments:

Post a Comment